Pharmaceutical Technology

JANUARY 8, 2023

In 2023, the pharmaceutical industry will mark 20 years since Xolair, an anti-IgE antibody, became the first biologic approved to treat asthma. Since then, the US FDA, EMA, and other agencies have approved several biologic antibodies targeting the inflammatory cytokines IL-4, IL-13, IL-5, and others for asthma. Approaches like bronchodilator inhalers focus on treating both asthma and chronic obstructive pulmonary disease (COPD).

FDA 119

FDA 119

pharmaphorum

JANUARY 8, 2023

Before the main event at JP Morgan 2023 even kicks off, we’re checking out the Sachs Associates Neuroscience Innovation Forum on Sunday. Speakers from Lilly, Boehringer Ingelheim, Takeda, and many more pharma firms big and small will present on key trends and developments in one of the most exciting areas of pharmaceutical and digital innovation. We’ll also wander over to the UC Davis Health Future & Health CEO Summit a little later this afternoon.

118

118

STAT

JANUARY 8, 2023

Day One Biopharmaceuticals said Sunday that a targeted therapy shrank tumors by at least 50% in a majority of children with the most common form of pediatric brain cancer, setting up a potential approval in a rare disease long overlooked by drugmakers.  The new data expand on earlier results released last year from 22 patients. Of the 69 pediatric low-grade glioma patients now evaluated, 44, or 64%, saw their tumors dwindle to less than half their original size, including three patients who

99

99

Hospital Pharmacy Europe

JANUARY 8, 2023

An analysis suggests that early emollient use prevents the development of atopic eczema in high-risk infants especially if an emulsion is used. The early prophylactic emollient use (EU) in high-risk infants appears able to prevent the development of atopic eczema (AE) with emollient emulsions likely to be the most effective, according to the findings of a network meta-analysis by Chinese researchers.

Hospitals 94

Hospitals 94

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

STAT

JANUARY 8, 2023

SAN FRANCISCO — What should be a triumphant return to the global biotech industry’s biggest annual event, “JPM Week,” after a two-year hiatus is turning as gloomy as Bay Area weather, with industry executives forecasting economic troubles in the year ahead. STAT asked more than 100 biotech and pharma executives, investors, and other insiders how they’re feeling about the state of the sector heading into 2023 and on the eve of the J.P.

98

98

Hospital Pharmacy Europe

JANUARY 8, 2023

Molnupiravir treatment failed to reduce both COVID-related hospitalisation and mortality among high-risk vaccinated adults in the community. Molnupiravir treatment for vaccinated, high-risk patients who become infected with COVID-19, failed to reduce both the rate of hospitalisation and death in comparison to usual care according to the findings of a large, randomised trial by members of the PANORAMIC Trial collaborative group.

Vaccines 52

Vaccines Hospitals Labelling 52

Med Ed 101

JANUARY 8, 2023

The ADA has released its 2023 guidelines. There are a significant number of impacts on medication therapy, and in this post I will outline my most important takeaways. I was also recently catching up with my friend and fellow pharmacist, Derek Borkowski who is the founder of pyrls.com and they again would like to share their excellent […]. The post 2023 ADA Guidelines – Free PDF and My 3 Big Takeaways appeared first on Med Ed 101.

52

52

STAT

JANUARY 8, 2023

Hospitals, health insurers, and other provider-related companies are returning in person to the J.P. Morgan Healthcare Conference for the first time since the coronavirus upended the health care economy. But the more things have changed since then, the more they have stayed the same. Health care gobbled up 18.3% of the U.S. economy by the end of 2021, according to the latest data from federal actuaries.

Insurance 97

Insurance Hospitals 97

Fierce Healthcare

JANUARY 8, 2023

Digital health funding slides 48% from 2021's peak. What's in store for 2023? hlandi. Sun, 01/08/2023 - 11:21.

52

52

The FDA Law Blog

JANUARY 8, 2023

By Larry K. Houck — In October, when pardoning those federally convicted of cannabis possession, President Joe Biden directed the Secretary of Health and Human Services (“HHS”) and the Attorney General “to initiate the administrative process to review expeditiously how marijuana is scheduled under federal law.” See President Biden Gives the Green Light for Significant Marijuana Reform, October 10, 2022.

Controlled Substances 64

Controlled Substances Inventory Control Compounding FDA 64

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

ISPE

JANUARY 8, 2023

The Road to Explainable AI in GXP-Regulated Areas Trudy Patterson Sun, 01/08/2023 - 13:23 Features January / February 2023 The Road to Explainable AI in GXP-Regulated Areas Elias Altrabsheh Martin Heitmann, FRM Patrick Steinmüller Bruna Pastori Vinco 1 January 2023 Recent advances in artificial intelligence (AI) have led to its widespread industrial adoption, with machine learning (ML) algorithms demonstrating advances in performance in a wide range of tasks.

Communication 52

Communication Documentation FDA 52